Free tool
FAERS Monitor: Qnasl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202813 or its brand name (Qnasl, Beclomethasone Dipropionate). Reports on generic versions are filed under their own applications.
Reports
7,437
Serious
5,923
80% of reports
Hospitalization
2,226
Death reported
558
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea557
- asthma369
- headache354
- vomiting349
- nausea344
- drug ineffective338
- fatigue337
- malaise318
- diarrhoea314
- cough306
- pneumonia298
- off label use251
- dizziness249
- wheezing222
- pain220
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 206 |
| 2005 | 233 |
| 2006 | 167 |
| 2007 | 230 |
| 2008 | 278 |
| 2009 | 151 |
| 2010 | 146 |
| 2011 | 221 |
| 2012 | 399 |
| 2013 | 273 |
| 2014 | 207 |
| 2015 | 234 |
| 2016 | 291 |
| 2017 | 158 |
| 2018 | 182 |
| 2019 | 217 |
| 2020 | 236 |
| 2021 | 319 |
| 2022 | 690 |
| 2023 | 691 |
| 2024 | 743 |
| 2025 | 725 |
| 2026 | 440 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,722 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| wheezingSignal | 222 | 10.6 | 9.3 | 1,924 |
| asthmaSignal | 369 | 9.3 | 8.4 | 2,717 |
| coughSignal | 306 | 3.1 | 2.8 | 435 |
| dyspnoeaSignal | 557 | 2.8 | 2.6 | 652 |
| pneumoniaSignal | 298 | 2.6 | 2.3 | 297 |
| vomitingSignal | 349 | 2.1 | 1.9 | 204 |
| malaiseSignal | 318 | 2.1 | 1.8 | 174 |
| headache | 354 | 1.6 | 1.4 | 81 |
| dizziness | 249 | 1.4 | 1.2 | 30 |
| diarrhoea | 314 | 1.4 | 1.2 | 33 |
| nausea | 344 | 1.2 | 1.1 | 15 |
| fatigue | 337 | 1.2 | 1.1 | 14 |
| pain | 220 | 1.0 | 0.9 | 0 |
| off label use | 251 | 0.8 | 0.7 | 11 |
| drug ineffective | 338 | 0.7 | 0.7 | 37 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.